ACSL4 Antibody

說明書

中文名稱：

ACSL4兔多克隆抗體
貨號：

CSB-PA283716
規格：

￥1100
圖片：
The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using CSB-PA283716(ACSL4 Antibody) at dilution 1/60, on the right is treated with fusion protein. (Original magnification: ×200)

The image on the left is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using CSB-PA283716(ACSL4 Antibody) at dilution 1/60, on the right is treated with fusion protein. (Original magnification: ×200)

Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-4: Hepg2 cells, hela cells, human fetal kidney tissue, Human liver tissue, Primary antibody: CSB-PA283716(ACSL4 Antibody) at dilution 1/650, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 15 seconds
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

O60488
基因名：

ACSL4
別名：

ACSL4; ACS4; FACL4; LACS4; Long-chain-fatty-acid--CoA ligase 4; Arachidonate--CoA ligase; Long-chain acyl-CoA synthetase 4; LACS 4
宿主：

Rabbit
反應種屬：

Human,Mouse,Rat
免疫原：

Fusion protein of Human ACSL4
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產品提供形式：

Liquid
應用范圍：

ELISA,WB,IHC

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:2000-1:10000
WB	1:1000-1:5000
IHC	1:50-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoA for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially activates arachidonate and eicosapentaenoate as substrates. Preferentially activates 8,9-EET > 14,15-EET > 5,6-EET > 11,12-EET. Modulates glucose-stimulated insulin secretion by regulating the levels of unesterified EETs. Modulates prostaglandin E2 secretion.
基因功能參考文獻：
1. The regulatory network among peroxisomal ABCD2:ACSL4:VLCFA serves as a novel regulator of cartilage homeostasis, and these data may provide novel insights into the role of peroxisomal fatty acid metabolism in pathogenesis of human osteoarthritis (OA). PMID: 30264402
2. Study demonstrated that ACSL4 was overexpressed in HCC. PMID: 28887439
3. studies have identified a novel substrate-induced posttranslational regulatory mechanism by which AA downregulates ACSL4 protein expression in hepatic cells. PMID: 24879802
4. Data show that ELOVL7, SOCS3, ACSL4 and CLU were upregulated while PRKAR1A and ABCG1 were downregulated in the phlegm-dampness group. PMID: 27928700
5. ACSL4 is not only a sensitive monitor of ferroptosis, but also an important contributor of ferroptosis. PMID: 27565726
6. Silencing of ACSL4 eliminated the 17beta-estradiol-induced increase in AA and EPA uptake. PMID: 28334272
7. ACSL4 plays a tumor-suppressive role in gastric cancer. PMID: 26949059
8. Suggest role for ACSL4 expression in development of castration-resistant prostate cancer. PMID: 26636648
9. we demonstrate that ACSL4 can be considered a novel activator of the mTOR pathway PMID: 26536660
10. In vitro analysis showed that a recombinant COX-2 enzyme more effectively metabolized 5(S)-HETE to 5-11-diHETE compared to COX-1 enzyme. PMID: 26282205
11. Upregulation of ACSL4 is responsible for the increase in triacylglycerol species containing long polyunsaturated fatty acids during activation of hepatic stellate cells. PMID: 25500141
12. Report PPARdelta-mediated regulatory mechanism for ACSL4 expression in liver tissue and cultured hepatic cells. PMID: 25645621
13. ACSL4 can serve as both a biomarker for, and mediator of, an aggressive breast cancer phenotype. PMID: 24155918
14. This study found no significant relationship between FACL4 and cognitive function. PMID: 20452052
15. conclude that in our model system exogenous fatty acids are channeled preferentially towards phosphatidylinositol by ACSL4 overexpression PMID: 24201376
16. MiR-205 down-regulates ACSL4 through targeting its 3'UTR in hepatoma cells. PMID: 24576478
17. The functional interaction between Acyl-CoA synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth. PMID: 22808264
18. the involvement of SHP2 activity in the regulation of the expression of the fatty acid-metabolizing enzyme ACSL4 PMID: 21903867
19. A total of six novel and 11 known single nucleotide polymorphisms were identified. Further studies are warranted to analyze the candidate genes at Xq11.1-q21.33. PMID: 21384559
20. CSL4 modulates PGE release from human erial smooth muscle cells. PMID: 21242590
21. Data suggest that the development of combinatory therapies that profit from the ACSL4, lipooxygenase and COX-2 synergistic action may allow for lower medication doses and avoidance of side effects. PMID: 21085606
22. Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma. PMID: 11731423
23. FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation PMID: 11889465
24. FACL4 is highly expressed in hippocampal and cerebellar neurons and may have a role in X linked mental retardation. PMID: 12525535
25. Overexpression of Fatty acid-CoA ligase 4 is associated with human hepatocellular carcinoma PMID: 12824887
26. FACL4 is involved in the hepatocellular carcinoma tumorigenesis and both cAMP and p38 MAPK pathways are associated with the regulation of FACL4 PMID: 15849811
27. Disruption of DMD and the absence of ACSL4 in a patient are responsible for neuromuscular disease and cognitive impairment. PMID: 16276108
28. FACL4 affects HCC cell growth and suggest that modulation of FACL4 expression/activity is an approach for treatment of HCC. PMID: 17934335
29. FACL4 might play a role in the growth of hepatic cancer cells. PMID: 18059177
30. No association between polymorphisms in the FACL4 (fatty acid-CoA ligase 4) gene and nonspecific mental retardation in Qin-Ba mountain region of China. PMID: 18614287
31. The common SNP (C to T substitution) in the first intron of the FACL4 gene is associated with altered Fatty Acid composition of plasma phosphatidylcholines in patients with metabolic syndrome . PMID: 19346733
32. ACSL4 can substitute the functions of dAcsl(l(2)44DEa in organismal viability, lipid storage and the neural wiring in visual center. PMID: 19617635
顯示更多

收起更多
相關疾病：

Mental retardation, X-linked 63 (MRX63); Alport syndrome with mental retardation, midface hypoplasia and elliptocytosis (ATS-MR)
亞細胞定位：

Mitochondrion outer membrane; Single-pass type III membrane protein. Peroxisome membrane; Single-pass type III membrane protein. Microsome membrane; Single-pass type III membrane protein. Endoplasmic reticulum membrane; Single-pass type III membrane protein. Cell membrane.
蛋白家族：

ATP-dependent AMP-binding enzyme family
數據庫鏈接：

HGNC: 3571

OMIM: 300157

KEGG: hsa:2182

STRING: 9606.ENSP00000339787

UniGene: Hs.268785

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human